Director Sale at Cytokinetics Signals Insider Activity Amid Drug Launches and Capital Raises
Cytokinetics' director, Edward M. Kaye, recently sold a substantial block of shares in the company's common stock. This transaction occurs against a backdrop of positive corporate developments for Cytokinetics Inc., including the launch of its heart drug Myqorzo in Germany, recent successful public offerings raising significant capital, and an elev…